SEPTInvestingStart Free
Stocks/PCRX/SEC Filings/8-K Nov 17, 2026

PCRX 8-K: Acquisition

Filed with the SEC on Nov 17, 2026 · accession 0001140361-26-044354

PCRX filed a 8-K (current report) with the SEC on Nov 17, 2026. Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary.

Summary of the filing

Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary. In connection with the merger, Pacira settled its 2.125% Convertible Senior Notes due 2029 into cash and terminated its credit agreement.

For details, click here →How to read a 8-K →

Key details

Cash consideration per share in tender offer$37
Aggregate principal amount of 2.125% Convertible Senior Notes due 2029 outstanding$287.5M
Amount outstanding under Credit Agreement repaid in full$96K
AcquirerViatris Inc.
Acquirer's wholly owned subsidiaryPeach Purchaser Sub Inc.
Trustee for convertible notesComputershare Trust Company, National Association
Administrative agent under terminated credit agreementWells Fargo Bank, National Association

✦ Ask GOAX AI about this filing — what it means for PCRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PCRX?

Click here

Frequently asked questions

What did PCRX file with the SEC on Nov 17, 2026?

PCRX filed a 8-K (Acquisition). Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary. In connection with the merger, Pacira settled its 2.125% Convertible Senior Notes due 2029 into cash and terminated its credit agreement.

What does a acquisition mean for PCRX stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other PCRX SEC filings

  • SC TO-T · Tender offerNov 12, 2026
  • 8-K · Legal settlementNov 12, 2026
  • 8-K · AcquisitionNov 5, 2026
  • 10-Q · Material agreementNov 5, 2026
  • SC TO-T · Tender offerOct 30, 2026
  • SCHEDULE 13G/A · SEC filingOct 30, 2026
  • SCHEDULE 13D/A · Activist campaignOct 13, 2026
  • 8-K · SEC filingOct 8, 2026
  • 8-K · SEC filingAug 4, 2026
  • 10-Q · Executive departureAug 4, 2026

Get alerts when PCRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
PCRX overviewPCRX analysisPCRX newsLatest SEC filings
Source: SEC EDGAR filing 0001140361-26-044354. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.